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ccording to the World Health Organization,
traumatic brain injury (TBI) will surpass many diseases
as the major cause of death and disability by the year
2020. It is estimated that 10 million people are affected
annually by TBI,
1 with the highest incidence among per-
sons 15 to 24 years of age and 75 years and older.
2 Since
TBI may result in lifelong impairment of an individual's
physical, cognitive, and psychosocial functioning, and
given the absence of a cure, TBI is a disorder of major
public health significance. 
Stem cell therapies hold promise for the treatment of
various human diseases, including TBI. However, the
lack of basic knowledge concerning basic stem cell sur-
vival, migration, differentiation, and integration in a real-
time manner when transplanted into damaged central
nervous system (CNS) remains a problem in attempts to
design stem cell therapies for CNS diseases. Several
types of stem cells have been investigated for the treat-
ment of diseases of the CNS. Embryonic stem cells
(ESCs) are pluripotent cells that have the capability to
differentiate into nearly all cell types, including neuronal
and glial fate cells.
3 However, the safety of transplanting
ESCs in humans has not been established so far, one
concern being the controversial formation of teratomas
following ESC-derived neural cell engraftment.
4 Neural
stem cells (NSCs) are multipotent cells with the poten-
tial to differentiate into neurons, oligodendrocytes, and
astrocytes and can be efficiently propagated in vitro.
5,6
However, many critical challenges remain using NSCs
for clinical applications, including the need for pure pop-
ulations of differentiated cells, inefficient tracking sys-
tems, and moderate cell survival after transplantation.
6,7
A third option is the use of mesenchymal stem cells
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Traumatic brain injury remains a major cause of death
and disability; it is estimated that annually 10 million
people are affected. Preclinical studies have shown the
potential therapeutic value of stem cell therapies.
Neuroprotective as well as regenerative properties of
stem cells have been suggested to be the mechanism of
action in preclinical studies. However, up to now stem
cell therapy has not been studied extensively in clinical
trials. This article summarizes the current experimental
evidence and points out hurdles for clinical application.
Focusing on a cell therapy in the acute stage of head
injury, the potential of encapsulated cell biodelivery as a
novel cell-therapeutic approach will also be discussed.
© 2011, LLS SAS Dialogues Clin Neurosci. 2011;13:279-286.
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tective and regenerative effects following cerebral
ischemia and TBI.
8,9The cells may be administered intra-
venously, but direct intracerebral administration has
been suggested to be potentially more effective.
10 It has
been shown that MSCs act mainly through the release
of neurotrophic and immunomodulatory peptides, as
opposed to through cell replacement or direct cell-to-cell
contact.
11,12 Given this, exogenous cells may well be a
source of trophic support, promoting endogenous repair
such as neurogenesis, angiogenesis, and synaptogenesis.
13
Mechanisms of action of 
stem cell therapy in CNS injury
The neuroprotective effect of stem cells for the treat-
ment of CNS injury has been shown in several preclini-
cal studies. However, the exact mechanism remains con-
troversial. Potential mechanisms currently under
investigation include engraftment and transdifferentia-
tion, modulation of the inflammatory milieu, and mod-
ulation of the systemic immunologic/inflammatory
response.
Lundberg et al
14 administered human mesenchymal stem
cells in the ipsilateral internal carotid artery of rats
which had been subjected to experimental TBI. Intra-
arterial transplantion of mesenchymal stem cells
resulted in CNS engraftment without thromboembolic
ischemia. Kuh et al
15 implanted human umbilical cord
blood-derived progenitor cells (HUCBCs) into the
injury site after spinal cord contusion in a rodent model.
The transplanted HUCBCs were differentiated into var-
ious neural cells, which were confirmed by double
immunofluorescence staining of bromodeoxyuridine
(BrdU) and glial fibrillary acidic protein (GFAP) and
microtubule-associated protein-2 (MAP-2) staining.
Locomotor testing showed functional improvement for
all time points tested up to 8 weeks after spinal cord
injury. Salazar et al
16 transplanted human neural stem
cells into immunodeficient NOD-scid mice 30 days post
spinal cord contusion injury. The transplanted mice
demonstrated significantly improved locomotor recov-
ery compared with vehicle controls using open field
locomotor testing and CatWalk gait analysis. The trans-
planted neural stem cells exhibited long-term engraft-
ment, migration, limited proliferation, and differentia-
tion predominantly to oligodendrocytes and neurons.
Also, differentiated NSCs integrated with the host as
was demonstrated by colocalization of human cytoplasm
with discrete staining for the paranodal marker con-
tactin-associated protein.
Dramatic cerebral responses following TBI comprise
inflammation, cell death, and modulation of trophic fac-
tor release. These cerebral modulations might be influ-
enced by stem cells. Walker et al
17 directly implanted
MSCs into the brains of rats which had been subjected
to TBI. Brain supernatant analysis showed an increase
in interleukin (IL)-6, which has both direct and indirect
neurotrophic effects on neurons.
18 Glazova et al
19
implanted neuronal phenotype ES cells in mice after
experimentally induced spinal cord injury.
Transplantation of the ES cells activated both brain-
derived neurotrophic factor IL-6 signaling pathways in
the host tissue, leading to activation of cAMP/PKA,
phosporylation of cofilin and synapsin I, and promoting
regenerative growth and neuronal survival. Given the
results of these preclinical studies, modulation of the
proinflammatory environment could afford neuropro-
tection.
Models of TBI invariably show activation of microglial
cells, although it is unclear whether such activation pro-
motes neuronal survival, or exacerbates neuronal dam-
age.
20 Also, adaptive immune responses play a role. For
example CD4+ T cells are observed in the substantia
nigra in TBI patients,
21 and in a model of spinal cord
injury, T cells isolated from diseased animals induced
transient hind limb paralysis and spinal cord inflamma-
tion when injected into naïve recipients.
22 B cells in this
model were also pathogenic. Although innate responses
are considered protective, there is a delicate balance
between the innate immune system and the adaptive
immune system in mediating either pathogenic or repair
processes under these conditions.
22 Walker et al
23 were
able to show that the intravenous injection of multipo-
tent adult progenitor cells after experimental TBI in
rodents preserved splenic mass and increased the num-
Selected abbreviations and acronyms
ESC embryonic stem cell
NSC neural stem cell
GLP glucagon-like peptide
MSC mesenchymal stem cell
hMSC human bone marrow-derived mesenchymal stem cells
CCI controlled cortical impact
MAP microtubule-associated protein
GFAP glial fibrillary acidic protein
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ber and proliferative rate of CD4+ T cells as well as the
production of IL-4 and IL-10 in stimulated splenocytes.
Hence, the colocalization of transplanted MAPC and
resident CD4+ splenocytes seems to be associated with
a global increase in IL-4 and IL-10 production and sta-
bilization of the cerebral microvasculature tight junction
proteins. Nemeth et al
24 administered bone marrow stro-
mal cells to mice before or shortly after inducing sepsis
by cecal ligation and puncture, and found monocytes
and/or macrophages from septic lungs made more IL-10
when prepared from mice treated with bone mesenchy-
mal stem cells (BMSCs) versus untreated mice, leading
to reduced mortality and improved organ function. 
Clinical translation of stem cell therapy in TBI
Step 1: Deciding on an approach
Despite the promising preclinical results described
above, there are problems to consider when trying to
translate these studies into a clinical setting. First and
foremost, the importance of engraftment and transdif-
ferentiation remains controversial. Intravenous infusion
of MSCs in rats which had been subjected to TBI failed
to result in significant acute or prolonged cerebral
engraftment of cells or to modify the recovery of motor
or cognitive function.
25Also, the transplantation of neu-
ronal stem cells into the ipsilateral or contralateral cor-
pus callosum of rats at 48 hours after severe experimen-
tal TBI failed to lead to proliferation of the implanted
cells, regardless of the site of implantation.
26 Cao et al
27
found pluripotent stem cells engrafted into the normal
or lesioned adult rat spinal cord to be restricted to a glial
lineage. Zheng et al
28 implanted neural stem cells derived
from Wistar rats into traumatized Sprague-Dawley rats
and studied the local lymphocyte infiltration. The histo-
logical examination and immunohistochemistry revealed
significant lymphocyte infiltration in the contusion, sug-
gesting that immunosuppressive treatment is necessary
following NSC transplantation. Considering these prob-
lems, this pathway may not be feasible for a clinical
translation at this point in time.
Therefore, “encapsulated cell biodelivery” has been put
forward as a novel clinical strategy for cell therapy in the
CNS. Encapsulation was originally introduced to assist
in allowing allogenic or xenogenic cell transplantation.
It appears that semipermeable hollow fibers,
29 as well as
spherical polymeric microcapsules,
30 protect cells trans-
planted into the brain from the immunological graft-ver-
sus-host response. As the capsules permit the free pas-
sage of nutrients, oxygen, and, indeed, smaller molecules,
the cells are maintained within the capsules, and can pro-
duce and deliver therapeutic peptides to the brain.
29,30
Encapsulated cells have already been used for the ther-
apy of diabetes mellitus,
31 amyotropic lateral sclerosis,
32,33
chronic pain,
34 Huntington’s disease,
35 and for the treat-
ment of malignant brain tumors.
36-38
Step 2: Preclinical studies 
Our group conducted a preclinical study testing the
effect of encapsulated native MSCs and encapsulated
glucagon-like peptide-1 (GLP-1) transfected MSCs in
experimental traumatic brain injury (controlled cortical
impact—CCI).
39
GLP-1 is an endogenous insulin-stimulating peptide
that is secreted from the gastrointestinal tract in
response to food intake.
40 GLP-1 receptors are also
expressed throughout the mammalian brain.
41
Stimulation of these receptors is associated with neu-
roprotective and neurotrophic activity.
42-44 GLP-1 has
been shown to improve learning and memory in GLP-1
receptor-deficient mice.
45The blood-to-brain delivery of
native GLP-1 is, however, affected because GLP-1
rapidly degrades, with a plasma half-life of between 1
and 2 min.
46 Hence, the cells were used as a “bioreactor”
which constantly releases GLP-1, while simultaneously
bypassing the blood-brain barrier.
A human bone marrow-derived, mesenchymal stem cell
line was used in this study. This cell line was immortal-
ized by transduction with the human telomerase reverse
transcriptase (hTERT) gene.
47 Following transfection
with a plasmid vector encoding a GLP-1 fusion gene, the
cells produced 8.7 kDa of dimeric GLP-1. The cells were
alginate encapsulated and stored in liquid nitrogen until
used. Each capsule contained approximately 2300 cells. 
Animals were randomized into five groups: controls (no
CCI); CCI-only; CCI + native human bone-marrow
derived mesenchymal stem cells (hMSC); CCI + GLP-
1 producing hMSC; and CCI + empty capsules. Twenty
capsules were implanted into the right lateral ventricle
immediately before CCI. Even though this technique
does not mimic the clinical setting, it was necessary in
order to ensure implantation of the encapsulated cells
into the ventricle, since the standard stereotactic coor-
dinates become invalid after the CCI due to contusion-
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related brain tissue shifting. On day 14, cisternal cere-
brospinal fluid (CSF) was sampled for measurement of
GLP-1 concentration, and brains were immuno-histo-
chemically assessed using specific antibody staining for
NeuN, MAP-2 and glial fibrillary acidic protein (GFAP).
In order to determine the viability and the GLP pro-
duction of the GLP-1 secreting hMSCs, nine healthy ani-
mals were implanted with 20 capsules using the same
stereotactic technique. Capsules were retrieved, and via-
bility and GLP-1 production rate was assessed after 2, 7,
and 14 days of cerebral transplantation. One third of the
retrieved capsules were stained with propidium iodide
(staining of nonvital cells) and SYBR Green (staining of
vital cells), and then visualized using fluorescence
microscopy. The remaining capsules were recultured to
measure the GLP-1 production rate. 
In both of the stem cell-treated CCI groups, hippocam-
pal cell loss was reduced, along with an attenuation of
cortical neuronal and glial abnormalities, as measured
by MAP-2 and GFAP expression. Anti-NeuN staining
demonstrated a major reduction of positively stained
neurons in the hilus of the dentate gyrus in the CCI-only
and CCI with empty capsule groups. This neuronal loss
was not observed in CCI animals implanted with native
hMSCs and with GLP-1-producing hMSCs. Similarly,
both Anti-GFAP and Anti-MAP-2 staining illustrated
that the staining pattern in the animals with native and
GLP-1 producing stem cells were very similar to those
of the healthy controls, whereas in the CCI-only and
CCI with empty capsules groups, increased immuno-
staining was observed, indicating reactive neuronal and
glial changes. However, the effects were more pro-
nounced in animals treated with GLP-1 secreting
hMSCs. In the CCI animals with GLP-1 producing
hMSCs, the CSF concentration of GLP-1 at day 14 was
17.3±3.4 pM. This concentration was significantly higher
than that in the remaining groups: 3.1±1.6 pM (CCI +
capsules without cells), 3.3±2.9pM (CCI + native hMSC)
and 2.4±0.7pM (CCI-only). No measurable GLP-1 con-
centrations (detection limit: 2 pM) were found in the
healthy control group.
Following a temporary cerebral implantation in healthy
rats, the mean in vitro GLP-1 production rate of the
hMCS explanted at day 2 was 3.68±0.49 fmol/capsule/h.
On day 7 the rate was 2.85±0.45 fmol/capsule/h, and on
day 14 it was 3.53±0.55 fmol/capsule/h. The production
rate of non-implanted capsules was 7.03 fmol/capsule/h.
Thus, the in vitro production rate of the encapsulated
GLP-1 stem cells, retrieved after temporary implanta-
tion in healthy rats, was maintained at about half the rate
of the nonimplanted GLP-1 secreting stem cells.
Independently of the duration of implantation, propid-
ium iodide and SYBR green fluorescence microscopy
revealed that more than 95% of the stem cells were
viable in the explanted capsules.
In a second study,
48 we tested the encapsulated cells
described above in a double transgenic mouse model of
Alzheimer’s disease (AD) after intraventricular implan-
tation at 3 months of age. Mice carrying mutations in the
amyloid precursor protein and presenilin-1 and -2 genes
develop AD-like deposits composed of A-beta at an
early age. Since A-beta deposits as well as inflammation
of the CNS are visible at 3 months starting in the frontal
cortex, stem cell implantation was performed at this age
to test whether early treatment may prevent the onset
of A-beta deposition and associated inflammation. A-
beta 40/42 deposition, and glial (GFAP) and microglial
(CD11b) immunoreactivity were investigated 2 months
after transplantation of either native MSC or MSC
transfected with GLP-1 and compared with untreated
controls. CD11b immunostaining in the frontal lobes was
significantly decreased in the GLP-1 hMSC group com-
pared with the untreated controls. Also, the plaque-asso-
ciated GFAP immunoreactivity was only observed in
one animal in the GLP-1 MSC group. A-beta 40 whole
brain (enzyme-linked immunosorbent assay, ELISA)
was decreased in both hMSC groups: 86.06 +/- 5.2 pg/mL
(untreated control) vs 78.67 +/- 11.2 pg/mL (GLP-1 MSC
group) vs 70.9 +/- 11.1 pg/mL. 
According to these experimental findings, encapsulated
native hMSCs possess anti-inflammatory and neuropro-
tective properties, which seem to be enhanced by genet-
ical engineering of the cells to secrete GLP-1. Therefore,
GLP-1-secreting hMSC capsules may have a therapeu-
tic potential in acute but also chronic neurological dis-
eases. 
Step 3: Clinical translation of encapsulated 
mesenchymal cell biodelivery of GLP-1
Translating our experimental findings, intracerebal hem-
orrhage (ICH) was chosen as disease model to investi-
gate the safety of encapsulated mesenchymal cell biode-
livery of GLP-1 in a phase I/II trial which is currently
ongoing.
49 Microencapsulated allogenic hMSCs are
transplanted into the brain tissue cavity after neurosur-
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approach is to improve the outcome after surgery for
ICH; the local, neuroprotective, and anti-inflammatory
cell therapy is targeting the secondary neuronal injury
in the perihematomal area occuring in the first weeks
after the bleeding.
Figure 1. Encapsulated mesenchymal cell biodelivery of GLP-1.Upper left: Human bone marrow-derived, mesenchymal stem cells producing GLP-1
are encapsulated with alginate (capsule diameter 500 to 600 µm, each capsule containing 3200 cells). As the capsules permit the free
passage of nutrients, oxygen, and, indeed, smaller molecules, the cells are maintained within the capsules, and can produce and deliver
therapeutic peptides to the brain. At the same time, cells transplanted into the brain are protected from the immunological graft-ver-
sus-host response. Upper right: The microcapsules are filled into a 1.5 x 1.5 cm-sized bag that is manually sutured from a polypropylene
mesh with pores of up to 300 µm. A 5-cm tether for fixation of the implant to the skull surface is applied. CSF can pass through the
pores providing the encapsulated cells with nutrients and oxygen. Lower left: The surgical hematoma is evacuated leaving the perihe-
matomal area. Lower right: The mesh bag is implanted into the hematoma cavity, and it is removed 2 weeks after implantation by a sec-
ond surgery. GLP, glucagon-like peptide; CSF, cerebrospinal fluid.
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In the clinical trial, each microcapsule contains about
3000 GLP-1 hMSC capsules, and approximately 7.8 x
106 cells are implanted. Since approval agencies are con-
cerned about possible long-term side effects due to stem
cell transplantation, the cells are not implanted into the
brain directly, but filled into a 1.5 x 1.5 cm-sized bag that
is manually sutured from a polypropylene mesh with
pores of up to 300 µm. A 5-cm tether for fixation of the
implant to the skull surface is applied. After surgical
hematoma evacuation, this mesh bag is implanted into
the hematoma cavity, and it is removed 2 weeks after
implantation by a second surgery. Figure 1 illustrates the
delivery system.
Safety assessments include MRI examinations, physical
and neurological examinations, NIH stroke scale
(NIHSS), Barthel Index (BI), clinical laboratory profile,
and any adverse events. Different risk levels are defined
that would eventually lead to the explantation of the
containment including the study medication (eg, sys-
temic infection, local inflammatory reaction, anaphylac-
tic reaction, seizures, unexpected neurological deterio-
ration or other unexpected adverse events). Follow-up
examinations continue until 6 months after surgery.
The interim evaluation of the first 11 patients revealed
neither side effects from the surgical interventions nor
implant-related side effects. Also, up to 30% of the trans-
planted MSCs survived the 2-week implantation period
and were still secretorily active after explantation. The
trial is still recruiting; a thorough assessment of the appli-
cation safety of the novel therapy, including a compre-
hensive analysis of neurological, radiological, and labo-
ratory parameters will be possible after completion of
the trial including a total of 20 cases. 
Step 4: Encapsulated cell biodelivery in TBI
According to the existing preclinical studies and the pre-
liminary results of the ongoing clinical trial in ICH
patients, GLP-1-secreting hMSC capsules might be an
effective treatment for TBI patients as well. Presumably,
the neuroprotective and anti-inflammatory properties of
the cell capsules are most effective in the acute stage
after TBI preventing ongoing secondary brain injury.
However, additional preclinical studies are required to
ascertain that the transplantation of cell capsules does
not increase the risk of edema or may cause increased
ICP. However, the preliminary radiological (MRI)
results in the ICH patients suggest that the cell capsules
may even decrease cerebral edema. 
Additionally, preclinical work must address the applica-
tion technique. Currently the therapeutic value of intra-
cerebral injection of cell capsules into a traumatic lesion,
ie, cerebral contusion, or into the cerebral ventricles is
not established. The intraventricular application has
been shown to be effective in our rodent TBI model;
however, it is controversial as to whether this application
route is also effective in humans. While the cerebroven-
tricular administration of trophic factors has influenced
the pathology of neurodegenerative disorders,
50,51 the
rapid clearance of CSF into the venous circulation has
been recognized as a substantial limitation to the phar-
makokinetics of this drug delivery route.
52,53 The only
reported clinical study investigating intraventricular, hol-
low fiber encapsulated cell biodelivery revealed only
minimally increased CSF concentration of the delivered
factor.
54 However, microencapsulation, as used in our
clinical study, allows for the transplantation of a signifi-
cantly higher number of cells, ie, millions compared with
only hundreds of thousands in the hollow fiber encap-
sulation.
55-57 Thus, the higher release rates that can be
achieved with the microencapsulation technique might
compensate for the rapid CSF clearance, and thereby
build up pharmacologically active CSF factor concen-
trations.
Also, it is not clarified, whether an enclosure, similar to
the mesh bag used in the ICH trial, is necessary for intra-
ventricular or intracerebral implantation. It might be
safe and effective to inject the cell capsules without such
containment. However, to validate this application, addi-
tional preclinical work addressing mainly acute and
chronic safety issues is required.
Outlook
While encapsulated cell biodelivery has a reasonable
perspective for a clinical application in traumatic brain
injury, the translation of the existing findings requires
extensive additional experimental studies.  ❏
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células madre en el daño cerebral 
traumático: el potencial  biogenerador de
células mesenquimáticas encapsuladas del
péptido-1 tipo glucagón
El daño cerebral traumático sigue siendo una impor-
tante causa de muerte e incapacidad, y se estima que
anualmente afecta a diez millones de personas. Los
estudios preclínicos han mostrado el potencial valor
terapéutico de los tratamientos con células madre.
Mediante los estudios preclínicos se ha sugerido que
el mecanismo de acción depende de las propiedades
neuroprotectoras y regeneradoras de las células
madre. Sin embargo, hasta la fecha la terapia con
células madre ha sido poco estudiada en ensayos clí-
nicos. Este artículo resume la evidencia experimental
actual y menciona los obstáculos para la aplicación
clínica. Enfocándose en la terapéutica celular durante
la etapa aguda del daño cerebral también se discute
el potencial biogenerador de células encapsuladas
como una nueva aproximación en la terapia celular. 
Translation clinique du traitement par 
cellules souches des lésions cérébrales 
traumatiques : le potentiel de biodélivrance
des cellules mésenchymateuses encapsulées
du peptide-1 analogue au glucagon
Les lésions cérébrales traumatiques restent une
cause majeure de décès et de handicap ; on estime
que 10 millions de personnes par an sont touchées.
Des études précliniques ont montré la valeur thé-
rapeutique potentielle des traitements par cellules
souches. Les propriétés neuroprotectives comme
régénératives des cellules souches semblent être le
mécanisme d’action retrouvé dans les études pré-
cliniques. Cependant, jusqu’à maintenant, le trai-
tement par cellules souches n’a pas été largement
étudié dans les études cliniques. En se concentrant
sur le traitement au stade aigu des lésions céré-
brales, nous analyserons le potentiel de la biodéli-
vrance des cellules encapsulées comme nouvelle
approche de thérapie cellulaire. 
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